يعرض 1 - 3 نتائج من 3 نتيجة بحث عن '"Abdulmajid Al Arfaj"', وقت الاستعلام: 0.81s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Association of Serum Zinc and Inflammatory Markers with the Severity of COVID-19 Infection in Adult Patients

    المؤلفون: Abdulaziz Saad Almasaud, Jamal Chalabi, Abdulmajid Al Arfaj, Ali Al Qarni, Ammar Alkroud, Zuheb Nagoor, Sana Akhtar, Jahangir Iqbal

    المصدر: Nutrients, Vol 15, Iss 2, p 340 (2023)

    مصطلحات موضوعية: COVID-19, SARS-CoV-2, zinc, inflammatory markers, viral infection, Nutrition. Foods and food supply, TX341-641

    وصف الملف: electronic resource

    Relation: https://www.mdpi.com/2072-6643/15/2/340; https://doaj.org/toc/2072-6643

    URL الوصول: https://doaj.org/article/a9bb170f42e441d487980937c618308c

    Find this article in full text from ProQuest Full Text Finder
    أضف إلى المفضلة
  2. 2
    Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial

    المؤلفون: Abdullatif Alarfaj, Manar Almaghaslah, Athari Alotaibi, Mohammad Bosaeed, Majed Al-Jeraisy, Yaseen M. Arabi, Hassan Almarhabi, Abderrezak Bouchama, Abdulmajid Al Arfaj, Mohammed Alzahrani, Abdulrahman Alsaedy, Majid Alshamrani, Omar Aldibasi, Malak Alharbi, Hajar Alqahtani, Badriah M. Almutairi, Khalid Ghalilah, Abdullah Bawazir, Nasser Alqahtani, Abdulhakeem O. Althaqafi, Nawaf M. Alyahya, Hawra Albayat, Sameera M. Al Johani, Ahmad Alaskar, Ebrahim Mahmoud, Jumana AlJishi, Faisal M. Alharbi, Hadeel Altayib, Saud AlEisa, Ahmad Alharbi

    المصدر: Infectious Diseases and Therapy

    مصطلحات موضوعية: Microbiology (medical), medicine.medical_specialty, Randomization, Combination therapy, medicine.medical_treatment, Population, Favipiravir, law.invention, Randomized controlled trial, law, Internal medicine, Medicine, education, Adverse effect, Moderate-to-severe, Original Research, Mechanical ventilation, education.field_of_study, SARS-CoV-2, business.industry, COVID-19, Hydroxychloroquine, Infectious Diseases, business, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc6d88b198d3a07df0676267abc18f8b
    https://doi.org/10.1007/s40121-021-00496-6

    Find this article in full text from Springer Verlag. Find this article in full text from ProQuest
    أضف إلى المفضلة
  3. 3
    Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT): An Open-Label, Multicentre, Randomised, Controlled Trial

    المؤلفون: Mohammed Bosaeed, Ebrahim Mahmoud, Ahmad Alharbi, Hadeel Altayeib, Hawra Albayat, Faisal Alharbi, Khalid Ghalilah, Abdulmajid Al Arfaj, Jumana AlJishi, Abdullatif Alarfaj, Hajar Alqahtani, Badriah M. Almutairi, Manar Almaghaslah, Nawaf M. Alyahya, Abdullah Bawazir, Saud AlEisa, Abdulrahman Alsaedy, Abderrezak Bouchama, Malak Alharbi, Majid AlShamrani, Sameera Al Johani, Majed Aljeraisy, Mohammed Alzahrani, Abdulhakeem O. Althaqafi, Hassan Almarhabi, Athari Alotaibi, Nasser Alqahtani, Yaseen Arabi, Omar Aldibasi, Ahmad Alaskar

    المصدر: SSRN Electronic Journal.

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::beee856b4cf4d6c0f3a4286f1a6aca75
    https://doi.org/10.2139/ssrn.3829663

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء